novartis_rm_logo_pos_rgb.png

Combined Clinics – Collaborative working within Rheumatology & Dermatology​
16th May 2022 | 17:45 – 19:30

Agenda
Click to enter
Technical Support
Prescribing Information & Adverse Event Reporting

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd.

UK | May 2022 | 208568

​

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

 

Cosentyx (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, adolescents & children from the age of 6 years who are candidates for systemic therapy & active psoriatic arthritis in adult patients, alone or in combination with methotrexate, when the response to previous disease-modifying antirheumatic drugs therapy has been inadequate.1

 

1.Cosentyx Summary of Product Characteristics

​

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com